EP Patent

EP4654974A1 — Method of treating hair loss disorders

Assigned to Sun Pharmaceutical Industries Inc · Expires 2025-12-03 · 0y expired

What this patent protects

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP4654974A1
Jurisdiction: EP
Classification: —
Expires: 2025-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.